{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '-', 'Requiring either corrective treatment or consultation, and/or', '-', 'Leading to IMP discontinuation or modification of dosing, and/or', '-', 'Fulfilling a seriousness criterion, and/or', '-', 'Defined as an AESI', 'Table 4 summarizes the reporting timelines for select AEs and laboratory abnormalities.', 'Table 4 - Summary of Adverse Event Reporting Instructions', 'Adverse event/laboratory abnormality', 'Reporting timeframe', 'Serious adverse event', 'Within 24 hours', 'Pregnancy', 'Within 24 hours', 'Overdose', 'Symptomatic', 'Within 24 hours', 'Asymptomatic', 'Routine', 'ALT elevation', 'ALT >5 ULN if baseline ALT is <2 ULN', 'Within 24 hours', 'ALT >8 ULN if baseline ALT is >2 ULN', 'Within 24 hours', 'ALT >3 ULN plus total bilirubin >2 ULN', 'Within 24 hours', 'Anaphylactic reactions or acute allergic reactions that require treatment', 'Within 24 hours', 'Severe injection site reactions that last longer than 24 hours', 'Within 24 hours', 'Serious infections or infections that are AESI (see Section 10.4.1.3 and Section 10.6.3)', 'Within 24 hours', 'AESI: adverse event of special interest; ALT: alanine aminotransaminase; ULN: upper limit of normal;', '10.4.4 Instructions for Reporting Serious Adverse Events', 'In the case of occurrence of an SAE, the Investigator or any designees must immediately:', 'ENTER (within 24 hours) the information related to the SAE in the appropriate screens of', 'the e-CRF; the system will automatically send a notification to the monitoring team after', 'approval of the Investigator within the e-CRF or after a standard delay.', 'SEND (preferably by fax or e-mail) a photocopy of all examinations carried out and the', 'dates on which these examinations were performed, to the representative of the monitoring', 'team whose name, fax number, and email address appear on the clinical trial protocol.', \"Care should be taken to ensure that the patient's identity is protected and the patient's\", 'identifiers in the clinical trial are properly mentioned on any copy of a source document', 'provided to the Sponsor. For laboratory results, include the laboratory normal ranges.', 'All further data updates should be recorded in the e-CRF as appropriate, and further', 'documentation as well as additional information (for laboratory data, concomitant', 'medications, patient status, etc) should be sent (by fax or e-mail) to the monitoring team', 'within 24 hours of knowledge of the SAE. In addition, every effort should be made to', 'further document any SAE that is fatal or life-threatening within a week (7 days) of the', 'initial notification.', 'Property of the Sanofi Group - strictly confidential', 'Page 104', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'A back-up plan (using a paper CRF process) is available and should be used when the', 'e-CRF system does not work.', 'Any SAE brought to the attention of the Investigator at any time after the end of the study', 'for the patient and considered by him/her to be caused by the IMP with a reasonable', 'possibility, should be reported to the monitoring team.', '10.4.5 Guidelines for Reporting Adverse Events of Special Interest', 'For AESIs, the Sponsor must be informed immediately (ie, within 24 hours), as per SAE', 'notification guidelines described in Section 10.4.4, even if not fulfilling a seriousness criterion,', 'using the corresponding pages of the CRF (to be sent) or screens in the e-CRF.', '10.4.6 Guidelines for Management of Specific Laboratory Abnormalities', 'Decision trees for the management of certain laboratory abnormalities by Sanofi are provided in', 'Appendix K.', 'The following laboratory abnormalities should be monitored, documented, and managed', 'according to the related flow chart in protocol appendices.', 'Neutropenia', 'Thrombocytopenia', 'ALT increase', 'Acute renal insufficiency', 'Suspicion of rhabdomyolysis', 'In addition, on treatment eosinophil counts > 3000 cells/L (3.0 giga/L) are to be reported as AEs.', '10.5 OBLIGATIONS OF THE SPONSOR', 'During the course of the study, the Sponsor will report in an expedited manner:', 'All SAEs that are both unexpected and at least reasonably related to the IMP (SUSAR), to', 'the regulatory authorities, IEC/IRBs as appropriate and to the Investigators.', 'All SAEs that are expected and at least reasonably related to the IMPs to the regulatory', 'authorities, according to local regulations.', 'In this study, some AEs are considered related to the underlying condition and thus will not be', 'considered unexpected (eg, wheezing related to asthma).', \"Any other AE not listed as an expected event in the Investigator's Brochure or in this protocol\", 'will be considered unexpected.', 'Property of the Sanofi Group - strictly confidential', 'Page 105', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}